A hybrid strategy for the prevention of cytomegalovirus-related complications in pediatric liver transplantation recipients

Transplantation

Volumn 87, Issue 9, 2009, Pages 1318-1324

  Madan, Rebecca P ^a   Campbell, Andrew L ^b   Shust, Gail F ^a   Kahn, Alissa R ^c   Wistinghausen, Birte ^c   Posada, Roberto ^c   Kerkar, Nanda ^c   Shneider, Benjamin L ^d   Emre, Sukru ^e   Herold, Betsy C ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b ABBOTT LABORATORIES   (United States)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^e YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cytomegalovirus; Pediatric liver transplantation; Preemptive therapy

Indexed keywords

CYTOMEGALOVIRUS ANTIBODY; DACLIZUMAB; GANCICLOVIR; HYPERIMMUNE GLOBULIN; METHYLPREDNISOLONE; PREDNISONE; TACROLIMUS; VALGANCICLOVIR; VIRUS DNA;

ADOLESCENT; ADULT; ANTIVIRAL ACTIVITY; ARTICLE; CHILD; CHILDHOOD DISEASE; CYTOMEGALOVIRUS INFECTION; DIAGNOSTIC APPROACH ROUTE; HIGH RISK POPULATION; HUMAN; HYBRID APPROACH; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MORTALITY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SHORT COURSE THERAPY; TREATMENT PLANNING;

ADOLESCENT; ANTIVIRAL AGENTS; CHILD; CHILD, PRESCHOOL; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; DNA, VIRAL; FOLLOW-UP STUDIES; GANCICLOVIR; HUMANS; INFANT; LIVER TRANSPLANTATION; POLYMERASE CHAIN REACTION; POSTOPERATIVE COMPLICATIONS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK REDUCTION BEHAVIOR; TIME FACTORS; VIREMIA;

EID: 67649600984     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e3181a19cda     Document Type: Article

References (32)

1. Fridell JA, Jain A, Reyes J, et al. Causes of mortality beyond 1 year after primary pediatric liver transplant under tacrolimus. Transplantation2002; 74: 1721.
2. Li L, Chaudhuri A, Weintraub LA, et al. Subclinical cytomegalovirus and Epstein-Barr virus viremia are associated with adverse outcomes in pediatric renal transplantation. Pediatr Transplant 2007; 11: 187.
3. Halme L, Hockerstedt K, Lautenschlager I. Cytomegalovirus infection and development of biliary complications after liver transplantation. Transplantation 2003; 75: 1853.
4. George MJ, Snydman DR, Werner BG, et al. The independent role of cytomegalovirus as a risk factor for invasive fungal disease in orthotopic liver transplant recipients. Boston Center for Liver Transplantation CMVIG-Study Group. Cytogam, MedImmune, Inc. Gaithersburg, Maryland. Am J Med 1997; 103: 106.
5. Husni RN, Gordon SM, Longworth DL, et al. Cytomegalovirus infection is a risk factor for invasive aspergillosis in lung transplant recipients. Clin Infect Dis 1998; 26: 753.
6. Humar A, Gillingham KJ, Payne WD, et al. Association between cytomegalovirus disease and chronic rejection in kidney transplant recipients. Transplantation 1999; 68: 1879.
7. Gupta P, Hart J, Cronin D, et al. Risk factors for chronic rejection after pediatric liver transplantation. Transplantation 2001; 72: 1098.
8. Webber SA, Naftel DC, Fricker FJ, et al. Lymphoproliferative disorders after paediatric heart transplantation: A multi-institutional study. Lancet2006; 367: 233.
9. Bingler MA, Feingold B, Miller SA, et al. Chronic high Epstein-Barr viral load state and risk for late-onset posttransplant lymphoproliferative disease/lymphoma in children. Am J Transplant 2008; 8: 442.
10. Singh N, Wannstedt C, Keyes L, et al. Efficacy of valganciclovir administered as preemptive therapy for cytomegalovirus disease in liver transplant recipients: Impact on viral load and late-onset cytomegalovirus disease. Transplantation 2005; 79: 85.
11. Singh N, Wannstedt C, Keyes L, et al. Valganciclovir as preemptive therapy for cytomegalovirus in cytomegalovirus-seronegative liver transplant recipients of cytomegalovirus-seropositive donor allografts. Liver Transpl 2008; 14: 240.
12. Couchoud C, Cucherat M, Haugh M, et al. Cytomegalovirus prophylaxis with antiviral agents in solid organ transplantation: a metaanalysis. Transplantation 1998; 65: 641.
13. Hodson EM, Jones CA, Webster AC, et al. Antiviral medications to prevent cytomegalovirus disease and early death in recipients of solidorgan transplants: A systematic review of randomised controlled trials. Lancet 2005; 365: 2105.
14. Diaz-Pedroche C, Lumbreras C, San Juan R, et al. Valganciclovir preemptive therapy for the prevention of cytomegalovirus disease in highrisk seropositive solid-organ transplant recipients. Transplantation2006; 82: 30.
15. Kalil AC, Levitsky J, Lyden E, et al. Meta-analysis: The efficacy of strategies to prevent organ disease by cytomegalovirus in solid organ transplant recipients. Ann Intern Med 2005; 143: 870.
16. Small LN, Lau J, Snydman DR. Preventing post-organ transplantation cytomegalovirus disease with ganciclovir: A meta-analysis comparing prophylactic and preemptive therapies. Clin Infect Dis 2006; 43: 869.
17. Limaye AP, Bakthavatsalam R, Kim HW, et al. Late-onset cytomegalovirus disease in liver transplant recipients despite antiviral prophylaxis. Transplantation 2004; 78: 1390.
18. Li F, Kenyon KW, Kirby KA, et al. Incidence and clinical features of ganciclovir-resistant cytomegalovirus disease in heart transplant recipients. Clin Infect Dis 2007; 45: 439.
19. D'Alessandro AM, Knechtle SJ, Chin LT, et al. Liver Transplantation in pediatric patients: twenty years of experience at the University of Wisconsin. Pediatr Transplant 2007; 11: 661.
20. Clark BS, Chang IF, Karpen SJ, et al. Valganciclovir for the prophylaxis of cytomegalovirus disease in pediatric liver transplant recipients. Transplantation 2004; 77: 1480.
21. Green M, Kaufmann M, Wilson J, et al. Comparison of intravenous ganciclovir followed by oral acyclovir with intravenous ganciclovir alone for prevention of cytomegalovirus and Epstein-Barr virus disease after liver transplantation in children. Clin Infect Dis 1997; 25: 1344.
22. Green M, Michaels MG, Katz BZ, et al. CMV-IVIG for prevention of Epstein Barr virus disease and posttransplant lymphoproliferative disease in pediatric liver transplant recipients. Am J Transplant 2006; 6: 1906.
23. Faqi AS, Klug A, Merker HJ, et al. Ganciclovir induces reproductive hazards in male rats after short-term exposure.HumExp Toxicol 1997; 16: 505.
24. Steininger C, Kundi M, Kletzmayr J, et al. Antibody maturation and viremia after primary cytomegalovirus infection, in immunocompetent patients and kidney-transplant patients. J Infect Dis 2004; 190: 1908.
25. Arthurs SK, Eid AJ, Pedersen RA, et al. Delayed-onset primary cytomegalovirus disease and the risk of allograft failure and mortality after kidney transplantation. Clin Infect Dis 2008; 46: 840.
26. Hibberd PL, Tolkoff-Rubin NE, Cosimi AB, et al. Symptomatic cytomegalovirus disease in the cytomegalovirus antibody seropositive renal transplant recipient treated with OKT3. Transplantation 1992; 53: 68.
27. Hibberd PL, Tolkoff-Rubin NE, Conti D, et al. Preemptive ganciclovir therapy to prevent cytomegalovirus disease in cytomegalovirus antibody-positive renal transplant recipients. A randomized controlled trial. Ann Intern Med 1995; 123: 18.
28. Turgeon N, Fishman JA, Basgoz N, et al. Effect of oral acyclovir or ganciclovir therapy after preemptive intravenous ganciclovir therapy to prevent cytomegalovirus disease in cytomegalovirus seropositive renal and liver transplant recipients receiving antilymphocyte antibody therapy. Transplantation 1998; 66: 1780.
29. Hodson EM, Jones CA, Strippoli GF, et al. Immunoglobulins, vaccines or interferon for preventing cytomegalovirus disease in solid organ transplant recipients. Cochrane Database Syst Rev 2007: CD005129.
30. Almyroudis NG, Jakubowski A, Jaffe D, et al. Predictors for persistent cytomegalovirus reactivation after T-cell-depleted allogeneic hematopoietic stem cell transplantation. Transpl Infect Dis 2007; 9: 286.
31. Gamadia LE, Remmerswaal EB, Weel JF, et al. Primary immune responses to human CMV: A critical role for IFN-gamma-producing CD4-T cells in protection against CMV disease. Blood 2003; 101: 2686.
32. Avetisyan G, Aschan J, Hagglund H, et al. Evaluation of intervention strategy based on CMV-specific immune responses after allogeneic SCT. Bone Marrow Transplant 2007; 40: 865.